Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
可测量残留病灶(MRD)作为急性髓系白血病(AML)临床药物审批的替代终点:来自 MRD 合作组织和 AML 临床治疗联盟的观点
期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.35960
Boyiadzis, Michael; Wei, Andrew H; Paiva, Bruno; Freeman, Sylvie D; Kaspers, Gertjan; Chyla, Brenda; Hersey, Sarah; Patel, Reshma; Maloney, Brian; Blanchet Zumofen, Marie-Helene; Van Hoef, Marlies; Wulff, Beate; Obourn, Vanessa; Patel, Shalaka; Lopes de Menezes, Daniel; Shi, Qian; Bengoudifa, Bourras-Rezki; Dimier, Natalie; Prior, Thomas J; Roboz, Gail J; Prebet, Thomas